Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564
CD70: An emerging target in cancer immunotherapyJulie Jacobs, Patrick Pauwels, Vanessa Deschoolmeester et al.|Pharmacology & Therapeutics|2015Cited by 225
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Martin Schüler et al.|The Lancet Oncology|2023Cited by 195
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D. Hellmann, Toshihiko Doi, Philippe Aftimos et al.|Clinical Cancer Research|2021Cited by 111
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Daniele Generali, Mario Giuliano et al.|Cancers|2021Cited by 19